RecruitingPhase 2NCT06027554

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults


Sponsor

UConn Health

Enrollment

60 participants

Start Date

Oct 7, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.


Eligibility

Min Age: 65 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mitoquinone Mesylate and Placebo capsule for people with aging, frailty, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMitoquinone Mesylate

MitoQ given 20 mg per day for 12 weeks.

DIETARY_SUPPLEMENTPlacebo capsule

Placebo capsule taken every day for 12 weeks.


Locations(1)

UConn Health

Farmington, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06027554


Related Trials